Company / PP&E (Net)
Thermo Fisher Scientific PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$10.6B
FY2025
5-year range
$8.3B / $10.6B
FY2021-FY2025
Trend
+13.5%
vs FY2024
Sector context
#5 of 132
Health Care
What the data says
Among 132 Health Care companies, Thermo Fisher Scientific is in the top 4% for pp&e (net). Improved from $9.4B to $10.6B over the past 2 years.
Based on SEC 10-K filings.
$10.6B in FY2025 with a 5-year CAGR of +12.3%. Top quartile in the Health Care sector.
Improved from $9.4B to $10.6B over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +4.4%
- 5-Year CAGR
- +12.3%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 132This company $10.6B Sector average $1.4B
▼
+636.3% above sector average
Key checks
Key Insights
- 5-year CAGR of +12.3%, indicating consistent growth.
- In FY2025, pp&e (net) increased 13.5% year-over-year.
- Ranks #5 out of 132 companies in the Health Care sector.
- Lowest pp&e (net) in the period was in FY2016.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.6B | +13.5% |
| FY2024 | $9.3B | -1.5% |
| FY2023 | $9.4B | +1.8% |
| FY2022 | $9.3B | +11.4% |
| FY2021 | $8.3B | +41.0% |
| FY2020 | $5.9B | +24.5% |
| FY2019 | $4.7B | +14.0% |
| FY2018 | $4.2B | +2.9% |
| FY2017 | $4.0B | +57.0% |
| FY2016 | $2.6B | +5.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026